Diana Shipping Urges Genco Shareholders to Vote for Nominees, Against Poison Pill & Equity Plan Ahead of Annual Meeting
Summary
Diana Shipping is making a final push in its proxy fight for Genco, urging shareholders to support its board nominees and reject Genco's defensive measures, while reiterating its $24.80 per share all-cash tender offer.
Key Events
-
Proxy Solicitation Update
Diana Shipping is actively soliciting votes for its two independent director nominees, Jens Ismar and Paul Cornell, for Genco's board at the Annual Meeting on June 18, 2026.
-
Opposition to Genco Proposals
Diana urges shareholders to vote AGAINST Genco's proposed equity incentive plan (which would dilute shareholders by approximately 3.8%) and the ratification of its poison pill, citing Institutional Shareholder Services (ISS) recommendations against both.
-
Live Tender Offer
Diana's all-cash tender offer of $24.80 per share for Genco remains open until June 26, 2026. This represents a premium over Genco's current stock price of $23.66.
-
Board Accountability Campaign
Diana is also urging shareholders to withhold votes for Genco nominees Basil G. Mavroleon and Arthur L. Regan, accusing them of entrenchment and approving excessive executive compensation.
Analysis
This filing from Diana Shipping is a critical update in its hostile takeover bid for Genco. Diana is urging Genco shareholders to vote for its independent director nominees and against Genco's poison pill and equity incentive plan at the upcoming Annual Meeting on June 18. The filing highlights that Diana's $24.80 per share all-cash tender offer, a premium to Genco's current stock price, remains active until June 26. The recommendations from Institutional Shareholder Services (ISS) against Genco's proposals add significant weight to Diana's campaign, potentially influencing institutional votes and pushing Genco's board to engage with the offer.
At the time of this filing, GNK was trading at $23.66 on NYSE in the Energy & Transportation sector, with a market capitalization of approximately $1B. The 52-week trading range was $12.84 to $27.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.